Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Edward Lee Carter: Are We Ready for FXIa Inhibitors?
Nov 19, 2026, 12:34

Edward Lee Carter: Are We Ready for FXIa Inhibitors?

Edward Lee Carter, Clinical Pharmacist Practitioner at U.S. Department of Veterans Affairs, shared a post on LinkedIn:

“Factor XIa inhibitors are here. Are our perioperative anticoagulation protocols ready?

The FDA’s November 9 approval of Sunharbo (asundexian) marks an important milestone in antithrombotic therapy.

But it also introduces a new challenge for anticoagulation stewardship.

What happens when a patient receiving a Factor XIa inhibitor needs surgery or an invasive procedure?

In a September 2026 review published in the Journal of Thrombosis and Haemostasis, Spyropoulos and Douketis examined the emerging evidence for perioperative management of Factor XI/XIa inhibitors.

Their findings raise an intriguing possibility:

  • Selected procedures may eventually be performed without interrupting certain FXI inhibitors.
  • Targeting FXI may reduce thrombus propagation while preserving more of normal hemostasis than conventional anticoagulant pathways.
  • Perioperative management could become simpler for some patients.

But promising evidence is not the same as an established clinical protocol.

Consider the newly approved asundexian:

FDA prescribing information: Interrupt at least 24 hours before elective surgery or invasive procedures. Restart once adequate hemostasis is established.

Bleeding considerations: Although overall major bleeding was similar to placebo in OCEANIC-STROKE, important bleeding signals were observed, including gastrointestinal bleeding and higher major bleeding rates in certain subgroups.

Unanswered questions: Urgent procedures, laboratory assessment, reversal strategies, and management of higher-bleeding-risk interventions remain areas requiring additional evidence.

And an important distinction: asundexian is approved for selected patients following non-cardioembolic ischemic stroke or high-risk TIA in combination with antiplatelet therapy.

Perioperative planning must therefore consider the entire antithrombotic regimen—not simply the FXIa inhibitor.

My takeaway:

We should resist the temptation to simply apply existing DOAC interruption protocols to this emerging class.

Different mechanisms, pharmacokinetics, and durations of action require agent-specific approaches.

The real opportunity for anticoagulation stewardship is to translate emerging evidence into practical, standardized, and clinically defensible decision support.

A new anticoagulant mechanism deserves a new level of perioperative preparation.

Are we ready?”

Edward Lee Carter: Are We Ready for FXIa Inhibitors?

More posts featuring Edward Lee Carter on Hemostasis Today.